Literature DB >> 15965668

Craniopharyngioma: a personal (Boston) experience.

R Michael Scott1.   

Abstract

BACKGROUND: The author reports his experience with 79 craniopharyngiomas operated since 1988. The review demonstrates that the biological behavior of these tumors is extremely variable, and that surgical management requires resourcefulness, judgement, and flexibility in the operating room.
RESULTS: Tumors will recur after total resection (15% in this series) and after subtotal resection and radiation therapy (22%) and adjuvant treatments of all types, and no treatment guarantees a cure.
CONCLUSION: The invasiveness of the tumor leads to difficult-to-treat long-term complications, particularly obesity and behavior disturbances. An extremely long-term follow-up of up to 20 years is necessary in many patients in order to determine the ultimate outcome of treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15965668     DOI: 10.1007/s00381-005-1221-6

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  4 in total

1.  Craniopharyngiomas in children: how radical should the surgeon be?

Authors:  Juraj Steňo; Ivan Bízik; Andrej Steňo; Viktor Matejčík
Journal:  Childs Nerv Syst       Date:  2010-11-12       Impact factor: 1.475

2.  Practical approach to childhood craniopharyngioma: a role of an endocrinologist and a general paediatrician.

Authors:  Maria A Kalina; Eliza Skala-Zamorowska; Barbara Kalina-Faska; Ewa Malecka-Tendera; Marek Mandera
Journal:  Childs Nerv Syst       Date:  2009-06-17       Impact factor: 1.475

Review 3.  The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngioma.

Authors:  G Minniti; V Esposito; M Amichetti; R Maurizi Enrici
Journal:  Neurosurg Rev       Date:  2009-01-23       Impact factor: 3.042

4.  Recurrent ectopic craniopharyngioma in the sylvian fissure thirty years after resection through a pterional approach: a case report and review of the literature.

Authors:  Shannon W Clark; Tyler J Kenning; James J Evans
Journal:  Nagoya J Med Sci       Date:  2015-02       Impact factor: 1.131

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.